| 标题 |
FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps |
| 网址 | |
| DOI |
10.1136/bmjebm-2022-111914
doi
|
| 其它 |
期刊:BMJ Evidence-Based Medicine 作者:John G Rizk; John C Lewin 出版日期:2022-04-21 |
| 求助人 | |
| 下载 | 暂无链接,等待应助者上传 |
PDF的下载单位、IP信息已删除
(2025-6-4)